Drug Profile


Alternative Names: AF-2838

Latest Information Update: 20 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Angelini Group
  • Class Analgesics; Anti-inflammatories; Antirheumatics; Indazoles; Propionates; Small molecules
  • Mechanism of Action Chemokine CCL2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Coronary artery restenosis; Diabetic nephropathies; Lupus nephritis; Pancreatitis; Rheumatoid arthritis

Most Recent Events

  • 22 Jun 2012 Bindarit is available for licensing as of 22 Jun 2012.
  • 30 Apr 2011 Angelini Group completes a phase II trial in Coronary artery restenosis prevention in Italy (NCT01269242)
  • 26 Oct 2006 Discontinued - Phase-II for Rheumatoid arthritis in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top